Why the study?
Does combined intracoronary adenosine and nicorandil improve angiographic and clinical outcomes in patients with AMI developing no-reflow during primary PCI?
Population
50 patients with acute myocardial infarction who developed no-reflow phenomenon during primary percutaneous…
Comparison
Combined intracoronary administration of… vs Intracoronary adenosine alone in addition to…
Design
Cohort
Follow-up
6 months
Authors
Loading...
May support adjunctive nicorandil for no-reflow in AMI PCI; hypothesis-generating and requires RCT confirmation.
Does combined intracoronary adenosine and nicorandil improve angiographic and clinical outcomes in patients with AMI developing no-reflow during primary PCI?
Combined intracoronary adenosine and nicorandil may be more effective than adenosine alone in treating no-reflow phenomenon and improving short-term clinical outcomes during primary PCI for AMI.
Lim et al. (2004) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: